It has been more than 50 years since the first reports of penicillin-and methyldopa-induced haemolytic anaemias emerged. Since these initial observations in 1966, that high-dose intravenous penicillin can result in a penicillin-antibodydependent immune haemolytic anaemia and patients receiving a-methyldopa developed haemolytic anaemia similar to warm autoimmune haemolytic anaemia, cases of patients having a drug-induced haemolysis has expanded greatly to include a myriad of different drugs. Indeed, there are now well over 100 drugs that have been described as causing immune-mediated haemolysis. The history of drug-induced immune haemolytic anaemia's can be subdivided into two different chapters: (1) The penicillin and methyldopa chapter and (2) the cephalothins and cefotetan chapter. In this review, these two chapters in the history of drug-induced immune haemolytic anaemias will be dissected, including the different mechanisms of haemolysis that have been proposed. These include so-called hapten, immune-complex, drug adsorption and autoimmune mechanisms. The biochemical and immunological mechanisms of drug-induced immune haemolytic anaemias will be discussed as well as important considerations in the approach to the laboratory investigation of these conditions in the blood bank and reference laboratories. An approach to the use of drug metabolites as well as a hypothesis as to how 'non-specific' drug adsorption occurs and how it can be prevented will be presented. The objective of this review will be to provide an up-to-date understanding of the types of drug-induced immune haemolytic anaemias, their differentiation in the laboratory and the biochemistry and immunology underlying these conditions.
Introduction
Immune haemolytic anaemias due to antibodies to red blood cells (RBCs) have been described for over 100 years; however, immune-mediated haemolysis caused by an immune response following ingestion of pharmaceutical drugs is relatively recent. Indeed, the first reports of drug-induced immune haemolytic anaemias (DIIHA) were in 1966. DIIHA caused by both penicillin therapy [1] and L-methyldopa (Aldomet) therapy [2] [3] [4] were published around the same time. Subsequent to these reports, a number of follow-up reports ensued, and a new area of acquired immune haemolytic anaemia and concern was established [5] [6] [7] . It has now been more than 50 years since penicillin and L-methyldopa were first described as causing DIIHA; however, the exact immunologic mechanism(s) of DIIHA has not been elucidated.
Development of in vitro serologic testing over the years to identify DIIHA has allowed for characterization of the serologic findings in these patients and formulation of ideas regarding the mechanism of the haemolytic anaemia [5] [6] [7] . The methods used in the serologic diagnosis and investigations of DIIHA have not really changed over the past 50 years (see [6, 7] for a detailed description of the methods used in the serologic investigation of DIIHA). However, the previous speculation as to the mechanisms of DIIHA may have created more confusion than resolved any mechanistic questions. For example, there have been Correspondence: Donald R. Branch, Centre for Innovation, Canadian Blood Services, 67 College St., Toronto, ON M5G 2M1, Canada E-mail: don.branch@utoronto.ca four different mechanisms previously proposed: (1) Drug adsorption, (2) immune complex, (3) non-specific protein adsorption and (4) autoimmune [6, 7] . Descriptions of drugs as just 'adsorbing' onto RBCs and 'non-specific' are not scientific terms. Reference to immune complexes, when there is proof that these do not exist in DIIHA, is counterproductive to an understanding of the immunologic mechanisms of anti-drug production [6] .
All drugs are small chemical molecules that have various core elements and side chains as well as reactive groups. Indeed, from an immunologic perspective, a drug is considered a hapten [8, 9] ; thus, it cannot elicit an immune response on its own but must bind specifically to a protein carrier molecule to elicit an immune response. With this in mind, the following review is based on the idea that any therapeutic small molecule drug acts as a hapten that has certain chemical characteristics that allows it to interact with RBCs, and that this interaction may affect different modes of immunologic response resulting in DIIHA, which can explain the in vitro serologic findings.
Hapten theory
In 1902, Karl Landsteiner performed experiments that indicated that any chemical compound (small molecule) could elicit an immune response [8] . He later termed these compounds 'haptens' [9] . As more investigators began to examine hapten-mediated immune responses, it became clear that haptens alone cannot elicit an immune response but require a protein carrier, such as albumin, in order to produce an antibody [10, 11] . It is now well established that the hapten-carrier complex stimulates the production of antibodies, which the unbound hapten cannot do, and it is the complex that becomes immunogenic (capable of eliciting an immune response). The carrier interacts through antigen-presenting cells to instruct helper T-cells to interact with B-cells that recognize the hapten-carrier complex to produce an antibody. Without the T-cell help provided by the carrier protein, no antibody can be produced to the hapten/drug. It is also well known that hapten-carrier mediated immune responses may not always occur but, when they do, they can include antibodies produced to only the hapten, to a combination of hapten-carrier, or to only the carrier [10, 11] . The differences in hapten-carrier responses probably relates to the affinity binding of the hapten to its carrier and immune status of the recipient.
A few investigators have used the hapten theory to come up with a unifying hypothesis for DIIHA that involves the drug as hapten and red blood cells as carrier [11, 12] . This translates to the current proposed mechanisms reported in this review as follows: drug-adsorption mechanism becomes hapten-specific mechanism (antibody produced to only the hapten); immune complex mechanism becomes the neoantigen mechanism (antibody produced to a combined drug-RBC antigen, a neoantigen); the modified membrane mechanism [the hapten modifies/alters the RBC membrane so that an antibody is produced that is cross-reactive with unmodified RBCs, and creates a state similar to warm autoimmune haemolytic anaemia (wAIHA); see Fig. 1 ].
How the RBC may act as carrier is well worked out for drugs that have a chemical structure known as a b-lactam moiety. These chemical structures are common for many antibiotics in the penicillin or cephalosporin category of antibiotics [5] [6] [7] (see Fig. 2 ). Under certain conditions, the b-lactam moiety can 'open up' creating a highly reactive amino group that can covalently link to other proteins via their free carboxy groups [7] . The RBC has many C-terminal carboxy regions exposed on its outer surface, including certain RBC antigens such as the Kell antigens.
Since not everyone who receives these antibiotics produces antibodies, there must also be some host factors involved, such as pH conditions, as b-lactam binding to proteins occurs optimally at alkaline pH. In addition to the b-lactam reactive group, there are a number of other chemical groups that could be reactive with RBC membranes to create a hapten-carrier complex [6, 7] .
Current proposed mechanisms of DIIHA

Hapten-specific mechanism
This particular mechanism of DIIHA is the classical hapten-carrier immune mechanism. Drug (hapten) binds with high affinity/avidity to a carrier protein, RBCs, which elicits an IgG anti-hapten-specific immune response specific to the drug. As the drug can directly bind to the RBC Fig. 1 A proposed unifying model of drug-induced immune haemolytic anaemias based on the hapten theory of antibody production. Figure is modified from [11, 12] . membrane via its b-lactam moiety, the IgG anti-drug causes a positive direct antiglobulin test due to IgG. An eluate or patient serum will react with normal RBCs that have the b-lactam antibiotic in question covalently linked, previously incorrectly termed the 'drug-adsorption' mechanism [6] . Indeed, there is no 'drug adsorption' but in reality these drugs bind to the RBCs via a chemical reaction that creates a covalent bond between the RBC and the drug through its b-lactam moiety. The covalent bonding can occur to some extent at physiological pH but is optimal at alkaline pH; thus explaining why use of pH 10 buffer is recommended to produce the drug-bound RBCs for in vitro testing. Also, confirmation of the hapten-specific mechanism is done by showing that hapten alone can inhibit the antibody reactivity in vitro [6, 11, 12] .
Neoantigen-dependent mechanism
In this case, the hapten binds to the RBC carrier but this creates a 'neoantigen', a new antigen that is a combination of the drug plus some RBC components [11, 12] . In vitro, serologic reactivity requires patient serum, drug and RBC to all be present in solution. When the drug is present either in vitro or in vivo, it creates the neoantigen [11, 12] , where the antibody produced is likely stabilized by binding to the combined drug-RBC neoantigen [6] . However, it appears that the antibody interaction is not very high affinity in vivo as antibody that binds to the neoantigen although, capable of activating complement, is not found by DAT testing, with only complement detectable. A DAT which is positive for C3 only is the serologic hallmark of this type of hapten-induced DIIHA; eluates, however, can sometimes be reactive in the presence of drug and RBCs. It may be that because one requires drug, patient serum and RBCs for in vitro serologic reactive that this mislead some investigators to call this the 'immune complex' mechanism. However, immune complex formation has been definitively ruled out as a mechanism in this DIIHA and this term should be abandoned [6] .
Cross-reactive autoantibody mechanism
This mechanism involves the hapten interacting with the RBC membrane in such a way that causes a modified or altered RBC protein which, through the immune system processing, results in the production of an antibody that reacts with the altered RBC antigen but also crossreacts with the normal antigen [13] . The best example is levo-3-(3,4-dihydroxyphenyl)-2-methylalanine or L-methyldopa (Aldomet) as even when the drug is removed, the antibody is still produced and reacts with all RBCs and resembles the autoantibodies found in wAIHA [2] [3] [4] [5] [6] [7] . Interesting, even though the autoantibody continues to 'crossreact' with normal RBCs when the drug is stopped, the haemolysis disappears [14] . Thus, although stopping the drug therapy stops the haemolytic anaemia, the reactivity with the patient's RBCs continues, demonstrating that the antibody is crossreactive to normal RBCs and pathogenic only when drug is present to provide the optimal altered RBC membrane target. This suggests that the optimal antigen for the autoantibody is the drug plus the RBCs and when there is no drug, the antibody is still crossreactive and the DAT continues to be positive, but due to a subtle change in orientation no longer interacts with Fc receptors on macrophages [14] . 
Immunoglobulin adsorption mechanism
This mechanism involves certain drugs such as cephalothin and tazobactam [5, 6, 15] and represents the old terminology of 'non-specific protein adsorption'. In these instances, the drug somehow causes various proteins to become bound to the RBCs [5] [6] [7] . Of course, one of these proteins would be IgG. In some cases, particularly with tazobactam, this bound IgG has the proper orientation to interact with the mononuclear phagocyte system (MPS) causing removal of the IgG-bound RBCs and haemolytic anaemia [5, 6] . Although the mechanism of this protein binding is not clear, it is known to be pH dependent and seems to occur with certain drugs having a b-lactam moiety [6, 7] . It has been proposed that these drugs have other reactive groups, besides the b-lactam, and that these other reactive groups can bind to the RBC under physiological pH and allow an exposed b-lactam to interact with and bind any other protein having a carboxy group [7, 15] . Credence is given to this idea as cephalothin can still bind to RBCs under acidic pH conditions but no longer can bind multiple proteins to the RBC [15] ; however, under more alkaline conditions the cephalothin can bind random proteins. This suggests that the b-lactam moiety is responsible for the random protein binding and led to the findings that binding cephalothin to RBCs at an acidic pH prevents the random protein binding and this approach can be used to investigate antibodies to cephalothin [6, 7, 15] .
Cefotetan and ceftriaxone
Currently, the most dangerous drugs causing DIIHA are two cephalosporins, cefotetan and ceftriaxone [5, 6] . These drugs cause severe haemolytic anaemia creating lifethreatening situations. Serologic testing has indicated that these drugs cause such severe haemolytic anaemia because they act via multiple mechanisms [5, 6] , hapten-specific, neoantgen and cross-reactive autoantibody. It is interesting to note that when comparing the chemical structures of these two drugs with all the other cephalosporin drugs, that they share some common chemical structures, most notably a sulphide linkage [see Fig. 2 ], which is not found on any of the other drugs in this class; whether or not this chemical similarity is involved in the ability of these two drugs to cause severe DIIHA remains to be determined.
Conclusions
It has been more than 50 years since the first descriptions of DIIHA. During this time, mostly serologic testing was developed with little attention paid to the chemical composition of the drugs or the immunology of the antibody production. This began to change around 1985 when Petz and Branch published their review [7] . Since then others have proposed that hapten theory, originally defined by Karl Landsteiner, can unify all of the proposed mechanisms of DIIHA [11, 12] . In this review, an attempt was made to use the idea of hapten-carrier to redefine the mechanisms of DIIHA.
